Stocks · News reference
Clearmind Medicine Initiates Phase lla, Double-Blind, Placebo-Controlled Phase I/IIa Clinical Trial Evaluating CMND-100 For Treatment Of AUD
Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Clearmind Medicine Stock Slides Friday: What's Happening?
Clearmind Medicine shares are trading lower Friday as investors weigh the biotech’s move to acquire a majority stake in an EV charging firm.
Clearmind Medicine Announces $2.5M Deal To Acquire 51% Stake In EV Wireless Charging Firm Charging Robotics, Plus $1.5M Loan At 4%; Expects Close Week Of September 7